.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Daiichi Sankyo
Deloitte
Mallinckrodt
Novartis
US Department of Justice
Fuji
Argus Health
Fish and Richardson

Generated: November 20, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,298,556

« Back to Dashboard

Which drugs does patent 8,298,556 protect, and when does it expire?


Patent 8,298,556 protects KYBELLA and is included in one NDA.

This patent has thirty-eight patent family members in twenty countries.

Summary for Patent: 8,298,556

Title:Methods and related compositions for the non-surgical removal of fat
Abstract: Compositions and methods useful in the non-surgical removal of localized fat deposits in patients in need thereof using pharmacologically active detergents are disclosed. The pharmacologically active detergent compositions can additionally include anti-inflammatory agents, analgesics, dispersion agents and pharmaceutically acceptable excipients but do not contain phosphotidylcholine. The pharmacologically active detergent compositions are useful for treating localized accumulations of fat including lower eyelid fat herniation, lipodystrophy and fat deposits associated with cellulite and do not require surgical procedures such as liposuction.
Inventor(s): Kolodney; Michael S. (Santa Monica, CA), Rotunda; Adam M. (Los Angeles, CA)
Assignee: The Regents of the University of California (Oakland, CA) Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (Torrance, CA)
Application Number:12/607,882
Patent Claim Types:
see list of patent claims
Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Kythera Biopharms
KYBELLA
deoxycholic acid
SOLUTION;SUBCUTANEOUS206333-001Apr 29, 2015RXYesYes► Subscribe► Subscribe METHOD FOR REDUCTION OF SUBMENTAL FAT
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,298,556

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,622,130Methods and compositions for the non-surgical removal of fat► Subscribe
8,846,066Methods and related compositions for reduction of fat and skin tightening► Subscribe
7,754,230Methods and related compositions for reduction of fat► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,298,556

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2005245002► Subscribe
Canada2567298► Subscribe
China101018553► Subscribe
China105233287► Subscribe
Cyprus1111974► Subscribe
Cyprus1112204► Subscribe
Denmark1748780► Subscribe
Denmark1758590► Subscribe
European Patent Office1748780► Subscribe
European Patent Office2572718► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
QuintilesIMS
US Department of Justice
Federal Trade Commission
Julphar
Moodys
Harvard Business School
Dow
McKesson
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot